Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087711 · ClinicalTrials.gov registry record · Phase 3
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,713
- Enrollment target
NCT00087711 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,713 participants.
The verdict
NCT00087711, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,713 participants
- Enrollment target
Study Summary
This study is a randomized Phase 3 study comparing pemetrexed and cisplatin combination to gemcitabine and cisplatin for the treatment of Non Small Cell Lung Cancer (NCSLC). Gemcitabine plus cisplatin is currently the standard of care for NSCLC. It is thought that pemetrexed plus cisplatin may be as effective and may have fewer side effects than the standard of care.
Interventions
- DRUG cisplatin
- DRUG pemetrexed
- DRUG gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,713 participants |
| Start Date | 2004-07 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087711
The ClinicalTrials.gov registry entry for NCT00087711 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,713 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00087711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087711 about?
NCT00087711 is a clinical study titled "A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer". This study is a randomized Phase 3 study comparing pemetrexed and cisplatin combination to gemcitabine and cisplatin for the treatment of Non Small Cell Lung Cancer (NCSLC). Gemcitabine plus cisplatin is currently the standard of care for NSCLC. It is thought that pemetrexed plus cisplatin may be as...
What is the current status of trial NCT00087711?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,713 participants. The study started on 2004-07. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00087711?
The interventions under investigation include: cisplatin (DRUG), pemetrexed (DRUG), gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00087711?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.